RT Journal Article
SR Electronic
T1 Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P577
VO 44
IS Suppl 58
A1 Victor Pinto-Plata
A1 Miguel Divo
A1 Caroline Owen
A1 Francesca Polverino
A1 Maria Laucho
A1 Bartolome Celi
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P577.abstract
AB Introduction:Plasma metabolic profiling of several aminoacids was reported in COPD patients and controls of the ECLIPSE cohort. However, a more comprehensive metabolomic profile and a comparative lung tissue analysis are lacking.Methods: We studied plasma metabolomic signature in a cohort of 60 COPD patients ( survivors and non survivors,follow up over 4 years) and 30 controls and compared to lung tissue metabolomic signature of 18 COPD patients (LVRS)and 12 controls (mild or no COPD). Lung function, exercise capacity and BODE index parameters were measured. Plasma/Lung metabolomics were studied using Liquid and Gas Chromatography / Mass Spectometry (LC/MS, LC/MS2, GC/MS).Results:Clinical parameters were worst in COPD non survivor groupView this table:Table 1. Plasma (87) and lung (73) metabolites were differentially expressed in COPD patients compared to controls. Palmitoyl sphingomyelin was identified as the most plausible analyte to be associated to lung parenchyma destruction and elevation in plasma level in COPD patients.Other metabolites (8) deserve further attention.Conclusion:Metabolomic analysis is an unbiased tool to identify important pathways associated to COPD pathogenesis.